{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:43:59Z","timestamp":1786981439508,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"publisher","award":["QUST-2-CPH-2019-9"],"award-info":[{"award-number":["QUST-2-CPH-2019-9"]}],"id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been approved for the treatment of DM, have gained attention for their cardioprotective effect. The mechanism by which SGLT-2 inhibitors exert their cardioprotective effect remains unclear. Recent studies have suggested that EMPA exerts its cardioprotective effect by inhibiting the Na\n                    <jats:sup>+<\/jats:sup>\n                    \/H\n                    <jats:sup>+<\/jats:sup>\n                    exchanger (NHE), a group of membrane proteins that regulate intracellular pH and cell volume. Increased activity and expression of NHE isoform 1 (NHE1), the predominant isoform expressed in the heart, leads to cardiac hypertrophy. p90 ribosomal s6 kinase (p90 RSK) has been demonstrated to stimulate NHE1 activity. In our study, H9c2 cardiomyoblasts were treated with angiotensin II (ANG) to activate NHE1 and generate a hypertrophic model. We aimed to understand whether EMPA reverses the ANG-induced hypertrophic response and to elucidate the molecular pathway contributing to the cardioprotective effect of EMPA. Our study demonstrated that ANG-induced hypertrophy of H9c2 cardiomyoblasts is accompanied with increased SGLT-1 and NHE1 protein expression, an effect which is prevented in the presence of EMPA. EMPA reduces ANG-induced hypertrophy through the inhibition of SGLT-1 and NHE1 expression.\n                  <\/jats:p>","DOI":"10.1007\/s11010-022-04411-6","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:30:21Z","timestamp":1648211421000},"page":"1865-1872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression"],"prefix":"10.1007","volume":"477","author":[{"given":"Nabeel","family":"Abdulrahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meram","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensa Mariam","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan Mahmoud","family":"Elkoubatry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Anood","family":"Al-Shamasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menatallah","family":"Rayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain Pierre","family":"Gadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Eldassouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwarul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6188-1145","authenticated-orcid":false,"given":"Fatima","family":"Mraiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"4411_CR1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S062","author":"AD Association","year":"2010","unstructured":"Association AD (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care. https:\/\/doi.org\/10.2337\/dc10-S062","journal-title":"Diabetes Care"},{"key":"4411_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4239\/wjd.v6.i6.850","volume":"6","author":"AT Kharroubi","year":"2015","unstructured":"Kharroubi AT, Darwish HM (2015) Diabetes mellitus: the epidemic of the century. World J Diabetes 6:850\u2013867. https:\/\/doi.org\/10.4239\/wjd.v6.i6.850","journal-title":"World J Diabetes"},{"key":"4411_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","volume":"103","author":"L Guariguata","year":"2014","unstructured":"Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137\u2013149. https:\/\/doi.org\/10.1016\/j.diabres.2013.11.002","journal-title":"Diabetes Res Clin Pract"},{"key":"4411_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.hfc.2019.02.003","volume":"15","author":"S Paolillo","year":"2019","unstructured":"Paolillo S, Marsico F, Prastaro M, Renga F, Esposito L, De Martino F, Di Napoli P, Esposito I, Ambrosio A, Ianniruberto M, Mennella R, Paolillo R, Gargiulo P (2019) Diabetic cardiomyopathy: definition, diagnosis, and therapeutic implications. Heart Fail Clin 15:341\u2013347. https:\/\/doi.org\/10.1016\/j.hfc.2019.02.003","journal-title":"Heart Fail Clin"},{"key":"4411_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"V Spigoni","year":"2020","unstructured":"Spigoni V, Fantuzzi F, Carubbi C, Pozzi G, Masselli E, Gobbi G, Solini A, Bonadonna RC, Dei Cas A (2020) Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol 19:46. https:\/\/doi.org\/10.1186\/s12933-020-01016-5","journal-title":"Cardiovasc Diabetol"},{"key":"4411_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ndt\/gfy407","volume":"34","author":"P Sarafidis","year":"2019","unstructured":"Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M (2019) SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant 34:208\u2013230. https:\/\/doi.org\/10.1093\/ndt\/gfy407","journal-title":"Nephrol Dial Transplant"},{"key":"4411_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M, Sabatine MS (2018) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"4411_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1152\/physiolgenomics.00064.2010","volume":"42","author":"J Xue","year":"2010","unstructured":"Xue J, Mraiche F, Zhou D, Karmazyn M, Oka T, Fliegel L, Haddad GG (2010) Elevated myocardial Na+\/H+ exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy. Physiol Genomics 42:374\u2013383. https:\/\/doi.org\/10.1152\/physiolgenomics.00064.2010","journal-title":"Physiol Genomics"},{"key":"4411_CR9","doi-asserted-by":"publisher","first-page":"e0122230","DOI":"10.1371\/journal.pone.0122230","volume":"10","author":"M Jaballah","year":"2015","unstructured":"Jaballah M, Mohamed IA, Alemrayat B, Al-Sulaiti F, Mlih M, Mraiche F (2015) Na+\/H+ exchanger isoform 1 induced cardiomyocyte hypertrophy involves activation of p90 ribosomal s6 kinase. PLoS ONE 10:e0122230. https:\/\/doi.org\/10.1371\/journal.pone.0122230","journal-title":"PLoS ONE"},{"key":"4411_CR10","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1152\/japplphysiol.00996.2014","volume":"118","author":"MB Nolly","year":"1985","unstructured":"Nolly MB, Pinilla AO, Ennis IL (1985) Cingolani HE and Morgan PE (2015) Cardiac hypertrophy reduction in SHR by specific silencing of myocardial Na(+)\/H(+) exchanger. J Appl Physiol 118:1154\u20131160. https:\/\/doi.org\/10.1152\/japplphysiol.00996.2014","journal-title":"J Appl Physiol"},{"key":"4411_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.yjmcc.2013.02.006","volume":"61","author":"M Karmazyn","year":"2013","unstructured":"Karmazyn M (2013) NHE-1: still a viable therapeutic target. J Mol Cell Cardiol 61:77\u201382. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.02.006","journal-title":"J Mol Cell Cardiol"},{"key":"4411_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia 60:568\u2013573. https:\/\/doi.org\/10.1007\/s00125-016-4134-x","journal-title":"Diabetologia"},{"key":"4411_CR13","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/circulationaha.117.030418","volume":"136","author":"M Packer","year":"2017","unstructured":"Packer M (2017) Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136:1548\u20131559. https:\/\/doi.org\/10.1161\/circulationaha.117.030418","journal-title":"Circulation"},{"key":"4411_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa323","author":"YJ Chung","year":"2020","unstructured":"Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, Swietach P, Shattock MJ (2020) Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvaa323","journal-title":"Cardiovasc Res"},{"key":"4411_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61:722\u2013726. https:\/\/doi.org\/10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"key":"4411_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","volume":"4","author":"O Iborra-Egea","year":"2019","unstructured":"Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lup\u00f3n J, Packer M, Heymans S, Zannad F, Butler J, Pascual-Figal D, Lax A, N\u00fa\u00f1ez J, de Boer RA, Bay\u00e9s-Gen\u00eds A (2019) Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC Basic Transl Sci 4:831\u2013840. https:\/\/doi.org\/10.1016\/j.jacbts.2019.07.010","journal-title":"JACC Basic Transl Sci"},{"key":"4411_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/hr.2011.196","volume":"35","author":"SJ Watkins","year":"2012","unstructured":"Watkins SJ, Borthwick GM, Oakenfull R, Robson A, Arthur HM (2012) Angiotensin II-induced cardiomyocyte hypertrophy in vitro is TAK1-dependent and Smad2\/3-independent. Hypertens Res 35:393\u2013398. https:\/\/doi.org\/10.1038\/hr.2011.196","journal-title":"Hypertens Res"},{"key":"4411_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00059-013-3849-4","volume":"39","author":"QQ Wu","year":"2014","unstructured":"Wu QQ, Zong J, Gao L, Dai J, Yang Z, Xu M, Fang Y, Ma ZG, Tang QZ (2014) Sulforaphane protects H9c2 cardiomyocytes from angiotensin II-induced hypertrophy. Herz 39:390\u2013396. https:\/\/doi.org\/10.1007\/s00059-013-3849-4","journal-title":"Herz"},{"key":"4411_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11010-015-2380-8","volume":"404","author":"M Mlih","year":"2015","unstructured":"Mlih M, Abdulrahman N, Gadeau AP, Mohamed IA, Jaballah M, Mraiche F (2015) Na(+)\/H (+) exchanger isoform 1 induced osteopontin expression in cardiomyocytes involves NFAT3\/Gata4. Mol Cell Biochem 404:211\u2013220. https:\/\/doi.org\/10.1007\/s11010-015-2380-8","journal-title":"Mol Cell Biochem"},{"key":"4411_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1161\/01.res.69.6.1476","volume":"69","author":"J Hescheler","year":"1991","unstructured":"Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G (1991) Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 69:1476\u20131486. https:\/\/doi.org\/10.1161\/01.res.69.6.1476","journal-title":"Circ Res"},{"key":"4411_CR21","doi-asserted-by":"publisher","first-page":"173420","DOI":"10.1016\/j.ejphar.2020.173420","volume":"888","author":"S Riaz","year":"2020","unstructured":"Riaz S, Abdulrahman N, Uddin S, Jabeen A, Gadeau AP, Fliegel L, Mraiche F (2020) Anti-hypertrophic effect of Na+\/H+ exchanger-1 inhibition is mediated by reduced cathepsin B. Eur J Pharmacol 888:173420. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173420","journal-title":"Eur J Pharmacol"},{"key":"4411_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11626-010-9368-1","volume":"47","author":"SJ Watkins","year":"2011","unstructured":"Watkins SJ, Borthwick GM, Arthur HM (2011) The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim 47:125\u2013131. https:\/\/doi.org\/10.1007\/s11626-010-9368-1","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"4411_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1152\/physiolgenomics.00133.2017","volume":"50","author":"N Abdulrahman","year":"2018","unstructured":"Abdulrahman N, Jaspard-Vinassa B, Fliegel L, Jabeen A, Riaz S, Gadeau AP, Mraiche F (2018) Na(+)\/H(+) exchanger isoform 1-induced osteopontin expression facilitates cardiac hypertrophy through p90 ribosomal S6 kinase. Physiol Genomics 50:332\u2013342. https:\/\/doi.org\/10.1152\/physiolgenomics.00133.2017","journal-title":"Physiol Genomics"},{"key":"4411_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","volume":"36","author":"S Kang","year":"2020","unstructured":"Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, Guzzardi DG, Svystonyuk DA, Pattar SS, Park DSJ, Turnbull JD, Duff HJ, Tibbles LA, Cunnington RH, Dyck JRB, Fedak PWM (2020) Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG outcome results. Can J Cardiol 36:543\u2013553. https:\/\/doi.org\/10.1016\/j.cjca.2019.08.033","journal-title":"Can J Cardiol"},{"key":"4411_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.738848","author":"S Puglisi","year":"2021","unstructured":"Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M, Reimondo G (2021) Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.738848","journal-title":"Front Endocrinol"},{"key":"4411_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvp190","volume":"84","author":"SK Banerjee","year":"2009","unstructured":"Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F (2009) SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84:111\u2013118. https:\/\/doi.org\/10.1093\/cvr\/cvp190","journal-title":"Cardiovasc Res"},{"key":"4411_CR27","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW, Coronel R, Weber NC, Zuurbier CJ (2018) Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol 9:1575. https:\/\/doi.org\/10.3389\/fphys.2018.01575","journal-title":"Front Physiol"},{"key":"4411_CR28","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"I Vrhovac","year":"2015","unstructured":"Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, Radovi\u0107 N, Jadrijevi\u0107 S, Aleksic I, Walles T, Sauvant C, Saboli\u0107 I, Koepsell H (2015) Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflug Arch 467:1881\u20131898. https:\/\/doi.org\/10.1007\/s00424-014-1619-7","journal-title":"Pflug Arch"},{"key":"4411_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12933-019-0889-y","volume":"18","author":"A Yoshii","year":"2019","unstructured":"Yoshii A, Nagoshi T, Kashiwagi Y, Kimura H, Tanaka Y, Oi Y, Ito K, Yoshino T, Tanaka TD, Yoshimura M (2019) Cardiac ischemia\u2013reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Cardiovasc Diabetol 18:85. https:\/\/doi.org\/10.1186\/s12933-019-0889-y","journal-title":"Cardiovasc Diabetol"},{"key":"4411_CR30","doi-asserted-by":"publisher","first-page":"41166","DOI":"10.1038\/srep41166","volume":"7","author":"A Van Steenbergen","year":"2017","unstructured":"Van Steenbergen A, Balteau M, Ginion A, Fert\u00e9 L, Battault S, Ravenstein CM, Balligand JL, Daskalopoulos EP, Gilon P, Despa F, Despa S, Vanoverschelde JL, Horman S, Koepsell H, Berry G, Hue L, Bertrand L, Beauloye C (2017) Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep 7:41166. https:\/\/doi.org\/10.1038\/srep41166","journal-title":"Sci Rep"},{"key":"4411_CR31","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1002\/ehf2.13024","volume":"7","author":"M Trum","year":"2020","unstructured":"Trum M, Riechel J, Lebek S, Pabel S, Sossalla ST, Hirt S, Arzt M, Maier LS, Wagner S (2020) Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes. ESC Heart Fail 7:4429\u20134437. https:\/\/doi.org\/10.1002\/ehf2.13024","journal-title":"ESC Heart Fail"},{"key":"4411_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00809-4","author":"K Jiang","year":"2021","unstructured":"Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, Xu S, Xu Y, Hwa J, Li J, Shang H, Xiang Y (2021) Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. https:\/\/doi.org\/10.1007\/s13238-020-00809-4","journal-title":"Protein Cell"},{"key":"4411_CR33","doi-asserted-by":"publisher","first-page":"112515","DOI":"10.1016\/j.biopha.2021.112515","volume":"146","author":"L Uthman","year":"2021","unstructured":"Uthman L, Li X, Baartscheer A, Schumacher CA, Baumgart P, Hermanides J, Preckel B, Hollmann MW, Coronel R, Zuurbier CJ, Weber NC (2021) Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na(+)](c)\/ROS-pathway in human endothelial cells. Biomed Pharmacother 146:112515. https:\/\/doi.org\/10.1016\/j.biopha.2021.112515","journal-title":"Biomed Pharmacother"},{"key":"4411_CR34","doi-asserted-by":"publisher","first-page":"20206","DOI":"10.1074\/jbc.274.29.20206","volume":"274","author":"E Takahashi","year":"1999","unstructured":"Takahashi E, Abe J, Gallis B, Aebersold R, Spring DJ, Krebs EG, Berk BC (1999) p90(RSK) is a serum-stimulated Na+\/H+ exchanger isoform-1 kinase. Regulatory phosphorylation of serine 703 of Na+\/H+ exchanger isoform-1. J Biol Chem 274:20206\u201320214. https:\/\/doi.org\/10.1074\/jbc.274.29.20206","journal-title":"J Biol Chem"},{"key":"4411_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG (2017) Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 16:9. https:\/\/doi.org\/10.1186\/s12933-016-0489-z","journal-title":"Cardiovasc Diabetol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04411-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04411-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04411-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T05:15:32Z","timestamp":1651641332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04411-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4411"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04411-6","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"12 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No human studies were carried out by the authors for this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}